Principal Financial Group
CCCC icon

Principal Financial Group’s C4 Therapeutics CCCC Stock Holding History

Principal Financial Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,238
Closed -$108K – 2383
2024
Q1 		$108K Sell
13,238
-1,515
-10% -$11.7K ﹤0.01% 2263
2023
Q4 		$83.4K Buy
14,753
+836
+6% +$1.91K ﹤0.01% 2289
2023
Q3 		$25.9K Hold
13,917
– – ﹤0.01% 2396
2023
Q2 		$38.3K Buy
13,917
+1,124
+9% +$3.61K ﹤0.01% 2378
2023
Q1 		$40.2K Buy
12,793
+1,428
+13% +$8.41K ﹤0.01% 2387
2022
Q4 		$67.1K Buy
+11,365
New +$94.2K ﹤0.01% 2344
2022
Q1 		– Sell
-6,570
Closed -$212K – 2552
2021
Q4 		$212K Sell
6,570
-1,536
-19% -$60.7K ﹤0.01% 2342
2021
Q3 		$362K Buy
8,106
+2,600
+47% +$111K ﹤0.01% 2256
2021
Q2 		$208K Buy
+5,506
New +$197K ﹤0.01% 2465

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Principal Financial Group's CCCC Position: Q2 2024 in Review

Principal Financial Group sold out of C4 Therapeutics (CCCC) in Q2 2024, closing a stake of 13,238 shares — an estimated $108K sold.

Principal Financial Group first reported a position in CCCC in Q2 2021 and held it in 9 quarters. The position peaked at $362K in Q3 2021. 115 funds tracked by Wall St. Rank hold CCCC as of Q2 2024.

  • Principal Financial Group reported no remaining C4 Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 13,238 C4 Therapeutics shares in Q2 2024, an estimated $108K.
  • Principal Financial Group first reported a position in C4 Therapeutics in Q2 2021 and held it in 9 quarters.
  • Principal Financial Group's C4 Therapeutics position peaked at $362K in Q3 2021.
  • 115 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.